New skin patch could ease nausea for stem cell transplant patients
NCT ID NCT04150614
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a granisetron skin patch works better than ondansetron pills for preventing nausea and vomiting in people getting chemotherapy before a stem cell transplant. About 90 patients will be enrolled and randomly assigned to one of the two treatments. The goal is to see which approach helps more patients avoid vomiting and the need for extra medication during the first 24 hours after chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
granisetron transdermal patch
What this could lead to
If the patch works better, it could offer a more convenient and effective way to control nausea and vomiting during stem cell transplant preparation.
What could go wrong
This is a small, early-phase study with only 90 participants, so results may not apply to everyone. The patch may not be more effective than the standard pill, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAUSEA WITH VOMITING CHEMOTHERAPY-INDUCED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Illinois Cancer Center
RECRUITINGChicago, Illinois, 60612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••